Home MarketAarti Drugs Ltd.

Aarti Drugs Ltd. Stock Info: As on 2018-02-23 15:44:45

Nse

613.15

6.15(1.01%)
Change%
52 Week Range
447.80
24.00
785.00
9.00
Open617.00
Day's Range485.60 - 728.40
Value Traded (in ₹ Cr.) 0.20

Bse

608.05

1.00(0.16%)
Change %
52 Week Range
456.25
24.00
784.80
9.00
Open616.45
Day's Range485.64 - 728.46
Value Traded (in ₹ Cr.) 0.10

Stock Exchange

Category No. Of Shares Share %
ForeignPromoters 0.00 0.00%
IndianPromoters 14,883,130.00 62.38%
Mutual Funds/UTI 877,023.00 3.68%
FII 166,618.00 0.70%
Employee 0.00 0.00%
Public 6,711,471.00 28.13%
Government 0.00 0.00%
Others 1,011,207.00 4.24%
More

Key Statistics

Valuation Measures
Market Cap / Sales Ratio 1.02
Basic EPS (Rs.) 27.37
Cash EPS 42.06
BVPerShare Excl 144.66
Operating Revenue 444.11
PBDITPerShare 70.90
Dividend 6.75
NPPerShare 27.37
Current Ratio 1.14
Quick Ratio 0.78
PriceToBV 3.14
Earnings 0.06
PBDIT Margin 15.96
PBT Margin 8.63
NP Margin 6.16
Return On Assets 6.28
Retention Ratios 75.33
Parameter Mar-16 (₹ Cr.) Yoy%change
Total Income 1,075.50
Total Expenses 982.66
EBITDA 171.70
PBT 92.84
PAT 66.29
Net Income 66.29
More
Parameter Mar-16 (₹ Cr.) 6M % change
Total Income 554.18
Total Expenses 486.08
EBITDA 50.03
PBT 45.77
PAT 33.72
Net Income 0.00
More
Total Assets
Total Assets
Parameter Mar-16 (₹ Cr.) Yoy%change
Total share capital 24.22
Net worth 350.31
Investments 11.12
Total Liability 1,054.70
Total debt 432.58
Net block 496.81
Total Assets 1,054.70
Parameter Mar-16 (₹ Cr.) 6M % change
Total share capital 24.22
Net worth 350.31
Investments 11.12
Total Liability 1,054.70
Total debt 432.58
Net block 496.81
Total Assets 1,054.70
Company Curr Price Prev. Close Change% W's Low/High

Abbott India Ltd.

5811.3 5754.4 0.99
5470.056125

Ajanta Pharma Ltd.

1374.45 1350.3 1.79
1311.31420

Albert David Ltd.

365.1 365.2 -0.03
357.4395.35

Alembic Ltd.

61.1 60.8 0.49
60.363.45

Alembic Pharmaceuticals Ltd.

561.9 563.7 -0.32
546.8585

Alkem Laboratories Ltd.

2181.3 2174.8 0.3
2115.12185

Alpa Laboratories Ltd.

43.75 41.7 4.92
38.346.6
Company Curr Price Prev. Close Change% W's Low/High

Aarey Drugs & Pharmaceuticals Ltd.

49.55 49.35 0.41
48.7554.15

Aayush Food & Herbs Ltd.

63.6 63.5 0.16
59.166.9

Abbott India Ltd.

5782.2 5746.8 0.62
5445.355950

ABL Bio-Technologies Ltd.

0.81 0.78 3.85
0.750.81

Addlife Pharma Ltd.

0.46 0 0
0.460.5

Adinath Bio-Labs Ltd.

0.3 0.31 -3.23
0.30.3

Advik Laboratories Ltd.

4.89 4.89 0
4.895.89
More
Parameter Mar-16(in ₹ Cr.)
Cash from operating activities 125.27
Cash from investing activities -87.40
Cash from financing activities -36.79
Net change in cash 1.07

Stock Held By Mutual Fund Schemes

Scheme Holding (%)
DSP BlackRock Micro-Cap Fund 0.85%

L&T’s arm bags orders worth Rs 1,266 cr

Larsen & Toubro has said that its construction arm has won orders worth Rs 1,266 crore across various business segments. The Buildings & Factories Business bagged orders worth Rs 928 crore. The order was bagged from a reputed government client to construct 284 Residential towers of G+3 floors under the Prime Minister Awas Yojana Scheme in various locations of Krishna District of Andhra Pradesh. The Power Transmission and Distribution business & Transportation Infrastructure business bagged an order from the Mumbai Metro Rail Corporation Ltd. (MMRC) worth Rs 338 Crore. The project involves Design, Engineering, Supply, Installation, Testing and Commissioning of Traction & Power Supply works for Mumbai Metro Line 3 (Colaba-Bandra-SEEPZ). This order has been secured against stiff competition from other major multi-national companies. Meanwhile, shares of the company were trading at Rs 1284 apiece, down 0.56 per cent from the previous close at 11:06 hours on BSE.

23-02-2018 11:00

Merck Q4 net profit jumps 49.84% at Rs 27.27 cr

The company reported standalone net profit of Rs 27.27 crore for the quarter ended December 31, 2017 as compared to Rs 18.20 crore in the same period last year, registering a year-on-year growth of 49.84 per cent. Net revenue of the company rose substantially by 26.72 per cent at Rs 304.13 crore in October-December quarter of this fiscal as against Rs 240.01 crore in the corresponding period last year. During October-December quarter, operating expenses increased by 20.50 per cent to Rs 273.41 crore from Rs 226.89 crore in year ago period. Other Income dipped by 33.58 per cent at Rs 5.40 crore versus (Dec'16 Rs 8.13 crore). Operating Profit surged by 24.57 per cent to Rs 30.72 crore as against Rs 24.66 crore in the year ago period, while Operating Profit Margin (OPM) contracted year-on-year to 1.66 per cent in December quarter. Taxation increased by 228.32 per cent at Rs 18.78 crore (Dec'16 Rs 5.72 crore).

23-02-2018 10:53

ITD Cementation Indi Q4 net profit up 36.82% at Rs 17.80 cr

The company reported standalone net profit of Rs 17.80 crore for the quarter ended December 31, 2017 as compared to Rs 13.01 crore in the same period last year, registering a year-on-year growth of 36.82 per cent. Net revenue of the company declined substantially by 30.70 per cent at Rs 467.43 crore in October-December quarter of this fiscal as against Rs 674.53 crore in the corresponding period last year. During October-December quarter, operating expenses dropped by 37.66 per cent to Rs 391.06 crore from Rs 627.27 crore in year ago period. Other Income grew by 138.07 per cent at Rs 14.57 crore versus (Dec'16 Rs 6.12 crore). Operating Profit surged by 60.54 per cent to Rs 76.37 crore as against Rs 47.57 crore in the year ago period, while Operating Profit Margin (OPM) expanded year-on-year to 131.77 per cent in December quarter. Interest grew by 4.46 per cent y-o-y to Rs 21.07 crore, while Taxation increased by 31.60 per cent at Rs 15.70 crore (Dec'16 Rs 11.93 crore).

23-02-2018 10:53

Visaka Indus. Q3 net profit zooms 164.56% at Rs 14.26 cr

The company reported standalone net profit of Rs 14.26 crore for the quarter ended December 31, 2017 as compared to Rs 5.39 crore in the same period last year, registering a year-on-year growth of 164.56 per cent. Net revenue of the company rose substantially by 20.34 per cent at Rs 241.84 crore in October-December quarter of this fiscal as against Rs 200.97 crore in the corresponding period last year. During October-December quarter, operating expenses increased by 14.71 per cent to Rs 207.41 crore from Rs 180.82 crore in year ago period. Other Income grew by 130.23 per cent at Rs 0.99 crore versus (Dec'16 Rs 0.43 crore). Operating Profit surged by 59.35 per cent to Rs 34.42 crore as against Rs 21.60 crore in the year ago period, while Operating Profit Margin (OPM) expanded year-on-year to 32.37 per cent in December quarter. Interest grew by 3.40 per cent y-o-y to Rs 4.87 crore, while Taxation increased by 138.56 per cent at Rs 7.61 crore (Dec'16 Rs 3.19 crore).

23-02-2018 10:53

Adani Transmission bags LOI from PFC Consulting Limited

Adani Transmission Ltd (ATL), the largest private power transmission companies operating in India has said that it has received the LOI from PFC Consulting Limited (A wholly owned subsidiary of Power Finance Corporation Limited) to construct, own, operate and maintain the transmission project in the state of Rajasthan. The project “Fatehgarh-Bhadla Transmission Limited” has approximately 200 Ckt kms of line at voltage level of 765 KV and one substation at voltage level of 400 KV. This project is primarily being constructed to wheel out renewable energy from state of Rajasthan to different beneficiaries within & outside of the state. This project has been awarded to ATL through a Tariff Based Competitive Bidding Process. With this project, ATL will strengthen its existing significant presence in Rajasthan with 2 operational transmission projects (i.e. Aravali & Maru transmission company Ltd) and 4 under construction assets i.e. Suratgarh Bikaner, PPP-8, PPP-9 & PPP-10. On completion of this acquisition, apart from largest distribution network, the cumulative transmission network of ATL will reach around 12000 ckt kms, out of which approximate 9000 ckt kms are under operation. The transformation capacity of ATL will also increase to 19,300 MVA from 35 substations (Including 8 EHV Substations under acquisition) spread across the Country. Meanwhile, shares of the company were trading at Rs 210.10 apiece, up 1.23 per cent from the previous close at 10:10 hours on BSE.

23-02-2018 10:02

Aarti Drugs Ltd - Press Release

Aarti Drugs Limited has informed the Exchange regarding a press release dated February 14, 2018, titled Press Release for the quarter December, 2017.

14-Feb-2018 05:22 PM

Aarti Drugs Ltd - Announcement under Regulation 30 (LODR)-Press Release / Media Release

Press Release for the quarter December, 2017

14-Feb-2018 04:53 PM

Aarti Drugs Ltd Q3 net profit up 34.82% at Rs 22.03 cr

The company reported standalone net profit of Rs 22.03 crore for the quarter ended December 31, 2017 as compared to Rs 16.34 crore in the same period last year, registering a year-on-year growth of 34.82 per cent. Net revenue of the company rose moderately by 16.99 per cent at Rs 308.21 crore in October-December quarter of this fiscal as against Rs 263.46 crore in the corresponding period last year. During October-December quarter, operating expenses increased by 15.01 per cent to Rs 257.42 crore from Rs 223.83 crore in year ago period. Other Income grew by 0.00 per cent at Rs 0.13 crore versus (Dec'16 Rs 0.00 crore). Operating Profit surged by 25.62 per cent to Rs 50.79 crore as against Rs 40.43 crore in the year ago period, while Operating Profit Margin (OPM) expanded year-on-year to 7.36 per cent in December quarter. Interest declined by 1.86 per cent y-o-y to Rs 8.44 crore, while Taxation increased by 84.17 per cent at Rs 11.05 crore (Dec'16 Rs 6.00 crore).

13-Feb-2018 04:46 PM

Aarti Drugs Ltd - Financial Result Updates

Aarti Drugs Limited has submitted to the Exchange, the financial results for the period ended December 31, 2017.

13-Feb-2018 03:09 PM

Aarti Drugs Ltd - Financial Results For The Quarter & Nine Months Ended 31St December, 2017.

Outcome of Board Meeting held today i.e. 13th February, 2018 pursuant to Regulation 33 and 30 read with Para A of Part A of Schedule III of SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015

13-Feb-2018 03:03 PM

Aarti Drugs Ltd - Announcement under Regulation 30 (LODR)-Press Release / Media Release

Press Release for the quarter December, 2017

14-Feb-2018 04:53 PM

Aarti Drugs Ltd - Financial Results For The Quarter & Nine Months Ended 31St December, 2017.

Outcome of Board Meeting held today i.e. 13th February, 2018 pursuant to Regulation 33 and 30 read with Para A of Part A of Schedule III of SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015

13-Feb-2018 03:03 PM

Aarti Drugs Ltd - Updates on Buyback Offer

Inga Capital Limited (Formerly Inga Capital Private Limited) (Manager to the Buyback Offer) has submitted to BSE a copy of
Letter of Offer for the attention of Equity Shareholders / Beneficial Owners of Aarti Drugs Ltd (Target Company).

07-Feb-2018 04:31 PM

Corporate Details

About Management

Aarti Drugs Limited was incorporated on 28th September, 1984 as a Private Limited Company. It was converted into a Public Limited Company on 1st July, 1992. The Company is presently engaged in the manufacture of MNI(300 TPA), MTZ (96 TPA), TNZ (84 TPA), DMZ (90 TPA) and Isoniazid (INH) (96 TPA). The Company started its commercial production is March 1987 at G.I.D.C. Industrial Estate, Sarigam, Dist. Valsad, Gujarat. This project was put up with financial assistance from Gujarat State Finance Corporation (GSFC) and Gujarat Industrial Investment Corporation (GIIC). The Company now proposes to expand the capacities for the above products, except INH and also proposes to set up a new plant for the manufacture of Glyoxal and Ammonium Sulphate. The Company has been consistently making profits and has maintained an unbroken dividend record since the year 1990-91. The Company is a part of the Alchemie Group of Companies. The Company is promoted by Mr. Chandrakant V.Gogri, Mr.Rajendra V.Gogri and Mr. Shantilal T. Shah. Mr. P.M. Patil and Mr. S. P. Nachane joined the Group in 1981. The Alchemie Group is a professionally managed, multi-product, multilocation Group comprising 24 manufacturing units with a total turnover of over Rs.100 crores for the year 1991-92. The products of the Group, exceeding 40, range from industrial chemicals and dye intermediates to bulk drugs and fine chemicals. The Group's customer list includes most of the leading chemical companies in the country. The Group's turnover and profits have increased five-fold in the last 5 years. It also recorded an export turnover of more than Rs. 30 crores in the year 1991-92. The Group units export products mainly to the general currency areas such as USA, UK, Switzerland and Germany. 2000 - The Company proposed to acquire 15,31,000 No. of equity shares of Alchemie Organics Ltd 33.44 per cent of the total paid-up capital of AOL held by the other promoters. 2002-Gauri Balankhe appointed as Compliance Officer of Aarti Drugs. 2004 -Aarti Drugs Ltd. has informed that the Company has changed its Registrar and Share Transfer Agent and Depository interface for Handling Depository related operations by appointing M/s Sharepro Services in place of M/s R & D Consultants Ltd w.e.f. January 16, 2004 subject to completion of necessary formalities as maybe prescribed in this regard. The address and telephone number of M/s Sharepro Services for all investors related services are as under: 1. M/s Sharepro Services, Unit : Aarti Drugs Ltd; 912, Raheja Centre, Free Press Journal Road, Nariman Point, Mumbai 400 021, Tel nos : 22881569, 22884527. 2. M/s Sharepro Services, Unit : Aarti Drugs Ltd; 912, Satam Estate, 3rd Floor, Above Bank of Baroda, Chakla, Andheri (East), Mumbai 400 099, Tel nos : 28215168, 28319828; Fax nos : 28375646. -Aarti bags European certification for three drugs -Delist from Ahmedabad Stock Exchange (ASE) with effect from October 15, 2004. 2006 -Aarti Drugs enters into JV with API Manufacturing Chinese Company - Aarti Drugs Ltd. has informed that Mr. Prakash Khedekar, Company Secretary & Compliance Officer of the Company has resigned from the position of Company Secretary & Compliance Officer with effect from October 31, 2006. Further, Mrs. Mona Patel, possessing requisite qualifications, has been appointed as Company Secretary & Compliance Officer of the Company with effect from November 01, 2006. 2009 - Aarti Drugs Ltd has has appointed Shri Krishnacharya Govindacharya Akamanchi & Prof. Sudhir Prakash B. Sawant as Independent Directors of the Company. 2010 -Aarti Drugs has recommended dividend of Rs. 5/- (50%) per share 2011 -Mr. Sunny D. Pagare, has been appointed as Company Secretary & Compliance Officer of the Company -Aarti Drugs has recommended Final Dividend of Rs. 2.5 /-per share (25%) 2012 -Mr. Adhish P. Patil, has been appointed as Chief Financial Officer of the Company -Aarti Drugs has declared Final dividend Rs. 3.00 (30%) per share 2013 -Aarti Drugs has recommended a Final Dividend of Rs. 4/- per share on Equity Shares of Rs. 10/- each. 2014 -Aarti Drugs has commenced the new R&D center at MIDC Tarapur. -Aarti Drugs has recommended a Final dividend @ Rs. 5.50 ps. (55%) per share. 2015 -Aarti Drugs Ltd has will participate at 'Centrum Pharma Day' Investor Conference -The Company has allotted the Bonus Shares to its shareholders in the Ratio of 1:1.

Registered Office

Plot Nos. D-277/278, TTC Industrial Area, Turbhe

,,,      ,

Registrar Details

Link Intime India Pvt. Ltd.